Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
EQRx Inc. Warrant (EQRXW)
| -83.0 | 13.8 | -54.5 | -95.9 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include... Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase I clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. Read more
Founder & Exec. Chairman of Board of Directors
Mr. Alexis A. Borisy A.M.
Founder & Exec. Chairman of Board of Directors
Mr. Alexis A. Borisy A.M.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of EQRx Inc Warrant (EQRXW) is $0.05 (NASDAQ) as of 08-Nov-2023 16:00 EDT. EQRx Inc Warrant (EQRXW) has given a return of -95.86% in the last 1 years.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
0.62
|
0.09
|
|
2021
|
-3.81
|
0.23
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
0.62
|
0.09
|
The 52-week high and low of EQRx Inc Warrant (EQRXW) are Rs -- and Rs -- as of 05-Apr-2026.
EQRx Inc Warrant (EQRXW) has a market capitalisation of -- as on 20-Nov-2023. As per SEBI classification, it is a company.
Before investing in EQRx Inc Warrant (EQRXW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.